Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. StockNews.com began coverage on shares of Bio-Path in a research report on Tuesday, August 9th. They issued a "sell" rating on the stock. HC Wainwright dropped their target price on Bio-Path from $12.00 to $9.00 and set a "buy" rating on the stock in a research report on Wednesday, May 18th.
Bio-Path Price Performance
Shares of NASDAQ:BPTH traded down $0.03 during midday trading on Monday, hitting $4.13. The stock had a trading volume of 7 shares, compared to its average volume of 49,855. Bio-Path has a fifty-two week low of $2.68 and a fifty-two week high of $8.62. The company's 50-day simple moving average is $3.86 and its 200 day simple moving average is $3.57. The firm has a market cap of $29.57 million, a P/E ratio of -2.58 and a beta of 1.48.
Bio-Path (NASDAQ:BPTH - Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). During the same period last year, the company posted ($0.43) earnings per share. Equities analysts expect that Bio-Path will post -1.89 EPS for the current fiscal year.